KR850001737A - N,n-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아미이드의 포합화합물의 제조방법 - Google Patents

N,n-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아미이드의 포합화합물의 제조방법 Download PDF

Info

Publication number
KR850001737A
KR850001737A KR1019840004894A KR840004894A KR850001737A KR 850001737 A KR850001737 A KR 850001737A KR 1019840004894 A KR1019840004894 A KR 1019840004894A KR 840004894 A KR840004894 A KR 840004894A KR 850001737 A KR850001737 A KR 850001737A
Authority
KR
South Korea
Prior art keywords
thiazolin
chloro
dimethyl
methyl
phenylsulfonamide
Prior art date
Application number
KR1019840004894A
Other languages
English (en)
Inventor
뤼디거 사이델 하인즈
Original Assignee
하인리히 벡커,베른하르트 벡크
훽스트 아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하인리히 벡커,베른하르트 벡크, 훽스트 아크티엔 게젤샤프트 filed Critical 하인리히 벡커,베른하르트 벡크
Publication of KR850001737A publication Critical patent/KR850001737A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

내용 없음

Description

N,N-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아미이드이 포합화합물의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. β-사이클로덱스트린 및 N,N-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아마이드로부터 수용성 산용액을 가열하면서 제조하고, 이로부터 포합화합물을 분리시킴을 특징으로 하는 N,N-디메틸-2-클로로-5-[3-메틸-2-(페닐아미노)-4-티아졸린-4-일]-페닐설폰아미이드와 β-사이클로덱스트린과의 포합화합물의 제조방법.
  2. 제1항에 있어서, β-사이클로덱스트린 및 N,N-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아마이드의 연합수용성 염산용액을 가열시키면서 제조하고, 이 용액을 냉각시키고, 침전된 포합화합물을 분리시키는 방법.
  3. 제1항에 있어서, β-사이클로덱스트린 및 N,N-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아마이드를 5 : 1, 바람직하게는 2 : 1의 비율로 사용하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840004894A 1983-08-16 1984-08-14 N,n-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아미이드의 포합화합물의 제조방법 KR850001737A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19833329517 DE3329517A1 (de) 1983-08-16 1983-08-16 Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate
DEP3329517.4 1983-08-16

Publications (1)

Publication Number Publication Date
KR850001737A true KR850001737A (ko) 1985-04-01

Family

ID=6206641

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840004894A KR850001737A (ko) 1983-08-16 1984-08-14 N,n-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아미이드의 포합화합물의 제조방법

Country Status (10)

Country Link
EP (1) EP0141076A1 (ko)
JP (1) JPS6058969A (ko)
KR (1) KR850001737A (ko)
AU (1) AU3196184A (ko)
DE (1) DE3329517A1 (ko)
DK (1) DK392384A (ko)
ES (1) ES535135A0 (ko)
GR (1) GR80116B (ko)
PT (1) PT79080B (ko)
ZA (1) ZA846327B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100503200B1 (ko) * 2000-09-05 2005-07-25 주식회사 포스코 석탄 건조설비의 석탄 불출량 제어장치

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6081166A (ja) * 1983-10-11 1985-05-09 Fujisawa Pharmaceut Co Ltd ２−ニトロオキシメチル−６−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法
JPH08777B2 (ja) * 1985-04-08 1996-01-10 武田薬品工業株式会社 経口用抗菌固型組成物
YU45837B (sh) * 1988-01-18 1992-07-20 LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100503200B1 (ko) * 2000-09-05 2005-07-25 주식회사 포스코 석탄 건조설비의 석탄 불출량 제어장치

Also Published As

Publication number Publication date
DK392384D0 (da) 1984-08-15
PT79080B (de) 1986-09-08
DE3329517A1 (de) 1985-02-28
GR80116B (en) 1984-12-14
ES8601694A1 (es) 1985-11-16
AU3196184A (en) 1985-02-21
JPS6058969A (ja) 1985-04-05
PT79080A (de) 1984-09-01
DK392384A (da) 1985-02-17
EP0141076A1 (de) 1985-05-15
ZA846327B (en) 1985-03-27
ES535135A0 (es) 1985-11-16

Similar Documents

Publication Publication Date Title
KR850003414A (ko) (2-니트록시메틸-6-클로로피리딘)과 (β-사이클로덱스트린)의 교합화합물의 제조방법
KR830008684A (ko) 면역 글로불린 접합체의 제조방법
KR850001149A (ko) 2-3차-부틸아미노-3'-클로로프로피오페논 말레에이트의 제조방법
KR850001737A (ko) N,n-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아미이드의 포합화합물의 제조방법
KR830004292A (ko) 벤조구아나민 유도체의 제조방법
KR840006230A (ko) 1-페닐-2-메틸-3-(1-피로리디닐)-1-프로판온 유도체의 제조방법
KR830004414A (ko) 마이코페놀산 유도체의 제조방법
KR880008871A (ko) 얇은 섬유-강화 수지 시이트의 제조방법
KR840000901A (ko) 옥센돌론 수성 현탁제의 제조방법
KR840001651A (ko) 폴리올레핀 모노필라멘트의 제조방법
KR840003639A (ko) 이속사졸로피리미딘 유도체의 제조방법
KR890003660A (ko) 4-(4-히드록시페닐)-시클로헥산올의 제조방법
KR870007917A (ko) 4-아세틸 이소퀴놀리논 화합물의 제조방법
KR920021069A (ko) 우뭇가사리(天草)를 이용한 청량 음료의 제조방법
KR830004249A (ko) 치환된 페닐피리딘의 제조방법
KR860004008A (ko) 부타놀유도체의 제법
KR830005197A (ko) 2,3-디히드로-5,6-디페닐-1,4-옥사티인 제조방법
KR860000139A (ko) 수축성 pvc재생필름의 제조방법
KR830005239A (ko) 아미노산 세파드록실(Cefadroxil)염의 제조방법
KR850001805A (ko) 고점도 히알루론산의 제조방법
KR910013375A (ko) 코우티드 벌브의 침전방법
KR880011174A (ko) 세펨 유도체의 제조방법
KR930001917A (ko) 악성 종양 치료제의 제조방법
KR910009186A (ko) 분말상 벌꿀제제 및 그 제조방법
KR890005983A (ko) 소형튜너의 코일장착방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid